Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been fully informed about the study and have agreed to take part by signing a consent form
• Adults aged 18 or older
• People who have been diagnosed with colorectal cancer that has spread and cannot be removed by surgery, and whose tumour has been confirmed to be microsatellite stable (MSS) — a specific characteristic of the tumour's genetic makeup
• People whose tumour shows a specific change in a gene called MET — either an amplification (too many copies of the gene) or overexpression (the MET protein is present at high levels) — confirmed through specific laboratory tests
• People whose cancer has continued to grow or spread after receiving two previous courses of standard cancer treatment, confirmed by imaging scans
• People who have at least one tumour that can be measured on imaging scans, according to standard criteria (RECIST 1.1)
• People with a good general level of physical functioning, rated 0 or 1 on a standard scale used in cancer trials (meaning fully active or able to carry out light activity)
• People whose life expectancy is estimated to be at least 3 months
• People whose blood counts meet minimum levels — including neutrophils, platelets, haemoglobin, and white blood cells — without the need for recent blood transfusions or growth factor medications
• People whose liver and kidney function test results fall within acceptable ranges as defined by the trial
• People whose blood clotting test results fall within acceptable ranges
• Women who could become pregnant must have a negative pregnancy test within 7 days before joining, must not be breastfeeding, and must be willing to use contraception during the trial and for 6 months after the last dose; male participants must also agree to use contraception during the trial and for 6 months after it ends

Who may not be able to join:

• People who have previously been treated with a MET inhibitor (a type of targeted cancer drug)
• People whose colorectal cancer has a different genetic profile called MSI-H or dMMR (a sign that the tumour has certain DNA repair problems)
• People whose tumour has a BRAF gene mutation and who have not yet received treatment with BRAF or MEK inhibitors
• People with serious active bleeding, active peptic ulcers, unhealed holes in the digestive tract, or fistulas (abnormal connections in the digestive tract)
• People who have had a severe allergic reaction to any of the study drugs or their ingredients
• People with serious uncontrolled infections or other serious uncontrolled medical conditions, or moderate to severe kidney problems (such as uncontrolled high blood pressure, uncontrolled diabetes, or ongoing serious infections)
• People with active hepatitis B or C infection, based on specific blood test thresholds
• People who are HIV positive
• People who have had or currently have another type of cancer, with some exceptions — such as certain well-controlled skin cancers, early-stage breast or cervical cancer, or other cancers that have been well-controlled without treatment for the past five years
• Women who are pregnant or breastfeeding, or people of childbearing potential who are unwilling to use contraception
• People who currently need treatment for another cancer
• People whom the trial investigators consider unsuitable for the study for other reasons

Important: Always verify eligibility with the trial site directly before applying.